Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:DMAC NASDAQ:SYRE NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$14.71-3.8%$11.85$2.60▼$16.96$1.31B-0.331.29 million shs234,591 shsDMACDiaMedica Therapeutics$6.63+0.2%$6.53$3.19▼$7.49$341.66M1.4221,721 shs80,482 shsSYRESpyre Therapeutics$22.41-3.6%$17.30$10.91▼$40.26$1.35B2.9674,034 shs92,515 shsTSHATaysha Gene Therapies$4.91-4.6%$3.56$1.05▼$5.51$1.34B0.993.89 million shs594,590 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals-0.52%+7.75%+14.88%+82.24%+228.11%DMACDiaMedica Therapeutics-2.22%-3.36%-2.93%+28.54%+54.31%SYRESpyre Therapeutics-1.02%+10.71%+56.25%+30.54%-28.31%TSHATaysha Gene Therapies+9.11%-0.19%+81.98%+91.45%+154.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$14.71-3.8%$11.85$2.60▼$16.96$1.31B-0.331.29 million shs234,591 shsDMACDiaMedica Therapeutics$6.63+0.2%$6.53$3.19▼$7.49$341.66M1.4221,721 shs80,482 shsSYRESpyre Therapeutics$22.41-3.6%$17.30$10.91▼$40.26$1.35B2.9674,034 shs92,515 shsTSHATaysha Gene Therapies$4.91-4.6%$3.56$1.05▼$5.51$1.34B0.993.89 million shs594,590 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals-0.52%+7.75%+14.88%+82.24%+228.11%DMACDiaMedica Therapeutics-2.22%-3.36%-2.93%+28.54%+54.31%SYRESpyre Therapeutics-1.02%+10.71%+56.25%+30.54%-28.31%TSHATaysha Gene Therapies+9.11%-0.19%+81.98%+91.45%+154.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.86Moderate Buy$16.7513.91% UpsideDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3385.91% UpsideSYRESpyre Therapeutics 3.00Buy$54.29142.29% UpsideTSHATaysha Gene Therapies 2.91Moderate Buy$9.6796.76% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, SYRE, AMLX, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025TSHATaysha Gene TherapiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$13.0010/17/2025AMLXAmylyx PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.0010/17/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/17/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/16/2025AMLXAmylyx PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $19.0010/8/2025AMLXAmylyx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SYRESpyre TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/3/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.0010/2/2025TSHATaysha Gene TherapiesRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $12.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M15.01N/AN/A$2.40 per share6.13DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ASYRESpyre TherapeuticsN/AN/AN/AN/A$7.04 per shareN/ATSHATaysha Gene Therapies$8.10M165.50N/AN/A$0.35 per share14.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)SYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest DMAC, SYRE, AMLX, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025DMACDiaMedica Therapeutics-$0.15N/AN/AN/AN/AN/A11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/6/2025Q3 2025AMLXAmylyx Pharmaceuticals-$0.45N/AN/AN/AN/AN/A11/6/2025Q3 2025SYRESpyre Therapeutics-$0.73N/AN/AN/AN/AN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/A8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A8.728.72DMACDiaMedica TherapeuticsN/A7.557.55SYRESpyre TherapeuticsN/A6.496.49TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%DMACDiaMedica Therapeutics10.12%SYRESpyre Therapeutics80.39%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%DMACDiaMedica Therapeutics7.30%SYRESpyre Therapeutics6.20%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableSYRESpyre Therapeutics7360.40 million56.66 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableDMAC, SYRE, AMLX, and TSHA HeadlinesRecent News About These CompaniesRaymond James Initiates Coverage of Taysha Gene Therapies (TSHA) with Strong Buy RecommendationOctober 22 at 4:19 AM | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.1% - Time to Buy?October 22 at 2:59 AM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesOctober 22 at 2:49 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Moderate Buy" by AnalystsOctober 22 at 2:47 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up - Time to Buy?October 21 at 11:59 AM | marketbeat.comRaymond James Financial Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)October 21 at 8:09 AM | marketbeat.comTaysha Gene Therapies initiated with a Strong Buy at Raymond JamesOctober 20 at 8:09 PM | msn.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Needham & Company LLCOctober 20 at 2:12 AM | americanbankingnews.comTaysha Gene Therapies' (TSHA) Buy Rating Reiterated at Chardan CapitalOctober 20 at 2:27 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 11.9% - Here's What HappenedOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Chardan CapitalOctober 18, 2025 | marketbeat.comHow Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment StoryOctober 17, 2025 | finance.yahoo.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 17, 2025 | finanznachrichten.deAstellas walks away from gene therapy pact with Taysha before pivotal trial launchOctober 17, 2025 | fiercebiotech.comFNeedham Reiterates Taysha Gene Therapies (TSHA) Buy RecommendationOctober 17, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Rett Syndrome ProgramOctober 16, 2025 | marketwatch.comTaysha Gene Therapies regains full rights to TSHA-102 programOctober 16, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 16, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - Should You Buy?October 15, 2025 | marketbeat.comTruist Financial Remains a Buy on Taysha Gene Therapies (TSHA)October 12, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMAC, SYRE, AMLX, and TSHA Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$14.70 -0.59 (-3.83%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.DiaMedica Therapeutics NASDAQ:DMAC$6.63 +0.01 (+0.21%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Spyre Therapeutics NASDAQ:SYRE$22.40 -0.85 (-3.63%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$4.91 -0.24 (-4.60%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
